Volanesorsen Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Volanesorsen Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
12
Registered trials
12
Result records
3
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Volanesorsen can convert its ASO profile and APOC3 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Volanesorsen (query alias: volanesorsen) |
|---|---|
| Modality / target | ASO; APOC3; APOC3 inhibitors |
| Highest global status | Approved |
| Originator | Akcea Therapeutics, Inc. |
| Active developers | Akcea Therapeutics Ireland Ltd., Akcea Therapeutics, Inc. |
The MCP disease footprint includes Familial chylomicronaemia syndrome. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| EUCTR2020-002997-28-NL | Phase 3 | 16 | To evaluate the efficacy of volanesorsen administered SC to adolescent and pediatric patients with Familial Chylomicronemia Syndrome (FCS) by assessing the following: • Percent change in fasting triglycerides from Baseline to the primary analysis time point at Week 13. | |
| NCT02910635 | Phase 1 | Completed | 52 | Not disclosed |
| DRKS00027982 | Not Applicable | Recruiting | 200 | Not disclosed |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
APOC3 inhibition with volanesorsen reduces hepatic steatosis in patients with severe hypertriglyceridemia
Phase 2/3; n=not disclosed; evaluation: Positive. Reported fields: HFF: placebo-adjusted % change from baseline = -24.2(95% CI, -5.6 to -0.6), P-Value = 0.009; HFF = -3.02 % ( (-5.60 to -0.60))
Volanesorsen, an antisense oligonucleotide to apolipoprotein C-III, increases lipoprotein lipase activity and lowers triglycerides in partial lipodystrophy.
Not Applicable; n=5; evaluation: not stated. Reported fields: LPL activity = 36 nEq/mL*min ; LPL activity = 21 nEq/mL*min
The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia
Phase 3; n=114; evaluation: not stated. Reported fields: Percent Change in Fasting Triglycerides (TG) From Baseline to Month 3(Least Squares Mean) = -0.9 percent change (95% Confidence Interval, -13.9 to 12.2); Percent Change in Fasting Triglycerides (TG) From Baseline to Month 3(Least Squares Mean): Difference in Least Squares Mean (LSM) = -70.3(95% CI, -85.4 to -55.3), P-Value = <0.0001; Percent Change in Fasting Triglycerides (TG) From Baseline to Month 3(Least Squares Mean): Difference in Least Squares Mean (LSM) = -70.3(95% CI, -85.4 to -55.3), P-Value = <0.0001
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Volanesorsen addresses Familial chylomicronaemia syndrome. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—ASO—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 3 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2024-01-29 | Acino signs an exclusive distribution agreement with the Swedish biopharmaceutical company Sobi in Kazakhstan | Approved | Financial terms not disclosed |
| 2023-10-31 | Sobi and Akcea Therapeutics on the North America rights to Tegsedi was terminated | Approved | Financial terms not disclosed |
| 2018-08-01 | PTC will distribute Akcea's Tegsedi and Waylivra in Latin America and select Caribbean nations. | NDA/BLA | US$26.0M stated total |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Class crowding and differentiation versus other PD-(L)1/VEGF agents
- Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
- Biomarker strategy, indication selection, and head-to-head endpoint execution
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
